List view / Grid view
11 November 2015 | By Victoria White
The clinical trial, a first-in-man study, looked at the efficacy of ONO/GS-4059 in the treatment of Chronic Lymphocytic Leukaemia and Non-Hodgkin Lymphoma patients...
11 November 2015 | By Victoria White
The results showed that belimumab administered subcutaneously plus standard of care (SoC) demonstrated significantly greater reductions in disease activity compared to placebo plus SoC...
11 November 2015 | By Victoria White
The transaction will be the largest in LEO Pharma’s more than 100-year history in terms of incremental turnover...
11 November 2015 | By Victoria White
HM12525A is a novel biologic GLP-1/Glucagon dual receptor agonist to treat diabetes and obesity...
11 November 2015 | By Victoria White
The approval is for the treatment of people with BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma...
10 November 2015 | By Victoria White
Anifrolumab is a new monoclonal antibody against the type I interferon (IFN) receptor that inhibits the activity of all type I IFNs, which play a central role in lupus...
10 November 2015 | By Victoria White
Psoriatic arthritis patients treated with ixekizumab for 24 weeks achieved significant improvements in signs and symptoms of their disease compared to placebo...
10 November 2015 | By Victoria White
CHS-0214 met its primary endpoints in a Phase 3 study in patients with moderate-to-severe chronic plaque psoriasis...
10 November 2015 | By Victoria White
The SMC also announced positive recommendations for Roche’s Avastin (bevacizumab) and Daiichi Sankyo’s Lixiana (edoxaban)...
10 November 2015 | By Victoria White
ABP 501 is being developed as a biosimilar candidate to adalimumab, an anti-TNF-α monoclonal antibody, which is approved in many countries for the treatment of inflammatory diseases...
10 November 2015 | By Victoria White
Acquiring Ocata will enable Astellas to establish a presence in ophthalmology and a leading position in cell therapy...
Baricitinib demonstrated superiority over adalimumab (Humira) after 12 weeks based on several critical measures of rheumatoid arthritis disease activity...
6 November 2015 | By Victoria White
Genvoya contains a new form of tenofovir that has not been previously approved...
6 November 2015 | By Victoria White
Sotagliflozin is an investigational new oral dual inhibitor of sodium-glucose cotransporters 1 and 2 which could be a potential treatment option for people with diabetes...
6 November 2015 | By Victoria White
The transaction will give AstraZeneca access to the potassium-binding compound ZS-9, a potential best-in-class treatment for hyperkalaemia...
